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The mechanism that controls the selective vulnerability of striatal neurons in Huntington’s disease is unclear. Brain-derived neurotro-
phic factor (BDNF) protects striatal neurons and is regulated by Huntingtin through the interaction with the neuron-restrictive silencer
factor. Here, we demonstrate that the downregulation of BDNF by mutant Huntingtin depends on the length and levels of expression of
the CAG repeats in cell cultures. To analyze the functional effects of these changes in BDNF in Huntington’s disease, we disrupted the
expression of bdnf in a transgenic mouse model by cross-mating bdnf/mice with R6/1 mice. Thus, we compared transgenic mice for
mutant Huntingtin with different levels of BDNF. Using this double mutant mouse line, we show that the deficit of endogenous BDNF
modulates the pathology of Huntington’s disease. The decreased levels of this neurotrophin advance the onset of motor dysfunctions and
produce more severe uncoordinated movements. This behavioral pathology correlates with the loss of striatal dopamine and cAMP-
regulated phosphoprotein-32-positive projection neurons. In particular, the insufficient levels of BDNF cause specific degeneration of the
enkephalinergic striatal projection neurons, which are the most affected cells in Huntington’s disease. This neuronal dysfunction can
specifically be restored by administration of exogenous BDNF.
Therefore, the decrease in BDNF levels plays a key role in the specific pathology observed in Huntington’s disease by inducing
dysfunction of striatal enkephalinergic neurons that produce severe motor dysfunctions. Hence, administration of exogenous BDNF may
delay or stop illness progression.
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Introduction
Neurodegenerative disorders such as Parkinson’s, Huntington’s,
or Alzheimer’s diseases are characterized by the loss of specific
neuronal populations. The mechanism responsible for the neu-
rodegenerative pattern of each disease is not known. In Hunting-
ton’s disease (HD), the CAG triplet expansion in the huntingtin
gene (htt) causes a primary loss of striatal projection neurons
that, in turn, leads to progressive motor impairment (Hickey and
Chesselet, 2003). Although htt is widely expressed in all animal
cells and its mutation is not tissue specific, the medium-sized
spiny striatal neurons, which express GABA, and dopamine and
cAMP-regulated phosphoprotein (DARPP)-32, undergo selec-
tive degeneration. Within the striatum, two separate subpopula-
tions of GABAergic neurons project to the external globus palli-
dus or to the substantia nigra pars reticulata and the internal
globus pallidus, originating the “indirect” and “direct” pathways,
respectively. The first of these subpopulations expresses en-
kephalin and is enriched in D2 dopamine receptors, whereas the
neurons that project to the substantia nigra and the internal glo-
bus pallidus express substance P and D1 dopamine receptors
(Gerfen, 1992). The primary affected striatal neurons are the en-
kephalinergic and those neurons that project to the substantia
nigra; however, striatal output to the internal globus pallidus is
relatively preserved (Richfield et al., 1995). Striatal interneurons
are also spared in this disorder (Sieradzan and Mann, 2001). This
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specific degeneration correlates with the appearance of choreic
movements (Reiner et al., 1988). However, neuronal degenera-
tion extends to other brain regions such as the cerebral cortex,
particularly in more advanced cases (Rubinsztein, 2002).
It has been suggested that mutant Htt initiates a cascade of
different events in the disease that converge in the specific cell
death of striatal neurons. A large number of abnormalities have
been reported in HD, including transcription deficits, energy im-
pairment, excitotoxicity, and lack of trophic support (Sugars and
Rubinsztein, 2003; Alberch et al., 2004). In this context, it has
been shown recently that Htt directly modulates the expression of
neuron-restrictive silencer factor (NRSF)-controlled neuronal
genes, including the brain-derived neurotrophic factor (bdnf) gene
(Zuccato et al., 2003). Thus, wild-type (wt) Htt stimulates the
production of BDNF, a neurotrophic factor for striatal neurons
(Perez-Navarro et al., 2000), whereas mutant Htt reduces it (Zuc-
cato et al., 2001). In keeping with these findings, BDNF is de-
creased in brain tissue from human HD patients (Ferrer et al.,
2000; Zuccato et al., 2001) and in some mice transgenic for mu-
tant htt (Zuccato et al., 2001; Duan et al., 2003; Zhang et al.,
2003).
Besides this evidence that mutant Htt regulates BDNF expres-
sion, it remains to be established whether downregulation of en-
dogenous BDNF participates in the specific motor dysfunctions
observed in HD. To study the function of endogenous BDNF in
HD, we generated a double-mutant animal by crossing bdnf het-
erozygous mice with a model of HD. Our present data show that
reduction of BDNF levels advances the age of onset and exacer-
bates the lack of motor control. This enlarged neurological pa-
thology correlates with morphological alterations, which shows
that BDNF plays a role in the specific degeneration of the striatal
enkephalinergic population.
Materials and Methods
Cell procedures. We used the conditionally immortalized striatal derived
neural stem cells, M213 (a generous gift from Dr. W. Freed, National
Institute on Drug Abuse, Bethesda, MD) (Giordano et al., 1993). For all
experiments, cells were grown and passaged at the permissive tempera-
ture of 33°C in DMEM (Invitrogen, Renfrewshire, Scotland) supple-
mented with 10% fetal calf serum (Invitrogen). Cells were transfected
using the rat neural stem cells nucleofector kit as described by the man-
ufacturer (Amaxa, Cologne, Germany). M213 cells (5 10 6) were resus-
pended in 200l of nucleofector solution (Amaxa) and mixed with 5g
of the required cDNA for each sample. Electroporation was performed
using the A-33 nucleofector program (Amaxa). We transfected three
different constructs, which allowed us to express the mutant exon 1 of the
htt gene with different CAG/CAA repeats: 47 (qp47), 72 (qp72), and 103
(qp103) (Kazantsev et al., 1999) (generously provided by Dr. George M.
Lawless, Cure HD Initiative, Reagent Resource Bank of the Hereditary
Disease Foundation, New York, NY).
For the study of BDNF secretion, cells were cultured in 24-well plates
for 24 hr after transfection and, thereafter, positively expressing cells
were purified by cell sorting. Cell sorting was performed on a
fluorescence-activated cell sorting Vantage SE (Becton Dickinson,
Mountain View, CA) using a single laser set at 488 nm. Cells were sorted
according to the endogenous enhanced green fluorescent protein
(EGFP) fluorescence intensity, and fluorescent channel 1 threshold was
set to collect only cells with high levels of expression except for qp103
clones, for which the gates were adjusted to collect separately the cells
with high and low levels of expression (see Fig. 1 B, inset). Sorting con-
ditions were as follows: drop drive of 23,000 drops per second; three
drops of sorting envelope; sample rate of 500 –1000 cells per second; drop
delay of 12.0. Sorted cells were collected in the cell culture medium
described above and seeded at a density of 10,000 cells/cm 2 onto 24-well
plates. One day later, the expression of EGFP was assessed in an inverted
fluorescent microscope. More than 80% of cells were positive, showing
larger and more abundant aggregates in cells transfected with longer
constructs. The levels of mutant htt directly correlate to the levels of
EGFP, because both are expressed as a fusion protein. Six days after
plating, the cell culture was removed and processed for the quantification
of the BDNF levels. Proteins from cell lysates were quantified to normal-
ize the levels of BDNF with respect to the microgram of protein from cells
for each well at the end of the experiment.
Mouse strains. To obtain double-mutant mice with mutant Htt and
low levels of BDNF (bDM; bdnf/ httm) or mice with mutant Htt and
low levels of neurotrophin (NT)-3 (n3DM; nt-3/ httm), we cross-
mated R6/1 mice (Mangiarini et al., 1996) with bdnf heterozygous (Ern-
fors et al., 1994a) or nt-3 heterozygous mice (Ernfors et al., 1994b),
respectively. F2 bdnf/ httm  bdnf/ httwt or F2 nt-3/ httm 
nt-3/ httwt inbred mice were used in this study. All experiments were
performed on male littermates from the F2 population to avoid strain
and sex differences. Mice were housed together in numerical birth order
in groups of mixed genotypes until they were 30 weeks of age with access
to food and water ad libitum in a colony room kept at a constant temper-
ature (19 –22°C) and humidity (40 –50%) on a 12 hr light/dark cycle. All
experiments were conducted in a blind-coded manner with respect to
genotype, and data were recorded for analysis by microchip mouse num-
ber. For developmental studies, some animals were killed 15 d after birth
(n  4 – 6 per genotype). All animal-related procedures were in accor-
dance with the National Institutes of Health guide for the care and use of
laboratory animals and approved by the local animal care committee of
the Universitat de Barcelona (99/01) and by the Generalitat de Catalunya
(99/1094). Animals were killed at 30 weeks of age, just before they dras-
tically lost weight and died. Body weight was measured twice each week.
For genotyping, DNA was obtained from tail biopsy and processed for
PCR. The primers used for DNA amplifications have been described
previously (Ernfors et al., 1994b; Mangiarini et al., 1996; Agerman et al.,
2003). PCR fragments were resolved in agarose gels, 2% for bdnf or nt-3
amplification and 1.5% for mutant htt analysis.
In vivo BDNF treatment. Administration of exogenous BDNF was
performed in 20-week-old R6/1 mice (n 5) and in 14-week-old bDM
(n 5) at the disease onset in each genotype. BDNF (4.5g per day) was
continuously infused using an osmotic minipump at a rate of 1 l per
hour (Alzet model 2001; Alza, Palo Alto, CA). A 28-gauge stainless steel
cannula was implanted into the left striatum (coordinates: anteroposte-
rior, 0.5; lateral, 2.0 from bregma and dorsoventral, 2.7 from
dura). The cannula was fixed on the skull with anchor screws and dental
cement. The metal inlet of the cannula was fitted to a tube connected to
the osmotic pump filled with either BDNF (187.5 ng/l in PBS) or PBS
alone (sham controls). The Alzet minipump was previously equilibrated
for 4 hr at 37°C in 0.9% NaCl. The pump was implanted subcutaneously
in the back of the animal. After 1 week, animals were killed and brains
were analyzed for in situ hybridization for neuropeptides.
Behavior analysis. Behavioral testing began at 3 weeks of age, when
mice were weaned. Tests were conducted regularly until week 30 to fol-
low the progression of each phenotype (n  9 –16 mice per group).
Motor coordination and balance were evaluated on the rotarod appara-
tus at several revolutions per minute as described previously (Carter et
al., 1999). In brief, animals were trained at a constant speed (24 rpm) for
60 sec. We performed four trials per day on three consecutive days, and
the latency to fall was recorded. No differences between groups were
detected during this period. After training, mice were evaluated once
every 2 weeks at 16, 24, and 32 rpm starting at 6 weeks of age, and the
number of falls in a total of 60 sec was recorded. The animals were put on
the rotarod several consecutive times until the addition of the latency to
fall off reached the total time of 60 sec. We compared the curves of the
behavior pattern and calculated the percentage of rotarod impairment as
described previously (Ferrante et al., 2002). The curves have been esti-
mated through generalized linear mixed models assuming a residual dis-
tributed under a Poisson distribution. The estimation approach used was
the Penalized Quasi-Likelihood, and the effects have been tested using
the F-Wald test. To analyze the individual differences in each time point,
we performed a one-way ANOVA followed by least significant difference
(LSD; t test) post hoc test.
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The walking footprint pattern, equilibrium,
vision, and muscular strength were evaluated at
30 weeks of age (n 9 –16 mice per group). The
footprint test was performed as described pre-
viously (Carter et al., 1999). Mice were trained
three consecutive times to walk in a corridor
that was 50 cm long and 7 cm wide. To register
the experiments, the forefeet and hindfeet of
the mice were painted with nontoxic black and
red ink, respectively, and then given one run.
The footprint pattern was analyzed for the
number of steps on the white paper, the stride
length was measured as the average distance of
forward movement between each stride, and
the forebase and hindbase widths were mea-
sured as the perpendicular distance between
the left and right footprints of a given step.
Equilibrium was analyzed by placing the
mice at the center of a raised (60 cm) horizontal
rod (50 cm long), and their latency to fall off the
rod was scored with a maximum of 60 sec. A flat
wooden rod (12 mm wide) was used in trials 1
and 2, and a cylindrical wire rod (14 mm diam-
eter) was used in trials 3 and 4. The distance
covered on the cylindrical rod was also regis-
tered and analyzed. The latency to fall off the
wooden rod was recorded with no differences
between groups found. The visual cliff avoid-
ance and the wire hang tests were performed
as described previously (Lione et al., 1999;
Gimenez-Llort et al., 2002).
For analyses of circling behavior, bDM were
injected intraperitoneally with amphetamine
(5 mg/kg) 1 week after unilateral BDNF infu-
sion. Mice were placed in circular cages and
connected to an automated rotometer. A com-
puter recorded the number of complete (360°)
turns made during a 5 min period. Mice were
allowed 15 min to habituate to the rotometer
before the administration of amphetamine.
The values were expressed as net total numbers
of full turns in 1 hr.
Results were expressed as the mean of several
animals, and error bars represent the SEM. Sta-
tistical analysis was performed using one-way
ANOVA followed by LSD post hoc test.
ELISA. BDNF or NT-3 contents were deter-
mined in duplicate by the Emax ImmunoAssay
system (Promega, Madison, WI), as described
previously (Perez-Navarro et al., 2000). For cell
cultures, the cell culture media were collected
after 6 d of plating cell after cell sorting. We
analyzed 50 l of supernatants from cell cul-
tures diluted 1:1 in block and sample buffer.
Values were normalized by the total protein
content of the cells in each well at the end of the
experiment and expressed as picogram of neu-
rotrophin per microgram of protein. For total
protein measurements, wells were washed
twice with PBS and then cells were homoge-
nized in lysis buffer (137 mM NaCl, 20 mM Tris-
HCl, pH 8.0, 1% Igepal, 10% glycerol, 1 mM
PMSF, 10 g/ml Aprotinin, 1 g/ml Leupep-
tin). Quantifications were performed using the
Detergent Compatible Protein Assay (Bio-Rad,
Hercules, CA) following the manufacturer
instructions.
For analysis of BDNF levels in brain tissue,
mice were deeply anesthetized in a CO2 cham-
Figure 1. The number of CAG repeats and the levels of mutant htt expression modulate the expression of BDNF. A, ELISA for
BDNF was performed on the culture media from wt M213 cells and subclones expressing exon 1 of mutant htt with 47 (qp47), 72
(qp72), and 103 CAG/CAA repeats (qp103). The expression of this neurotrophin decreases as the number of repeats is longer. The
scheme at the top shows the structure of qp constructs, which expresses a fusion protein of the first 90 amino acids of the mutant
htt and the EGFP. The right panels are photomicrographs of transfected cells with the qp47, 72, and 103 constructs, which show the
mutant htt inclusions. CMV, Cytomegalovirus. Scale bar, 50m. B, Transfected cells that express different levels of qp103 were
collected by cell sorting (inset shows sorting gates), and BDNF levels were assessed. The amount of BDNF in culture media is
inversely proportional to the levels of expression of qp103. ***p0.001 compared with wt cells;p0.05 compared with qp47
or qp72; ##p 0.005 compared with low levels of qp103 expression. C–G, BDNF levels are not affected by the mutant exon 1 of Htt
in R6/1 (bdnf/ httm). C–E, In situ hybridization demonstrates that mutant htt does not change the levels of bdnf expression
either in the motor cortex ( D) or in the sensorial cortex ( E). C, A Representative coronal section (bregma,1.1 mm) of bdnf in situ
hybridization of the four genotypes analyzed. F, G, In addition, the levels of BDNF protein detected by ELISA are not modified by
mutant htt in the cortex ( F) or in the striatum ( G). The only changes in mRNA or protein are detected in bdnf/mice with or
without mutant htt ( C–G). *p 0.05, **p 0.005, and ***p 0.001 compared with wt mice (bdnf/ httwt);p 0.005
andp 0.001 compared with R6/1 mice (bdnf/ httm).
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ber at 30 weeks of age (n  4 per genotype).
Their cortex and striatum were dissected out on
ice and rapidly frozen using CO2 pellets. Sam-
ples were then homogenized in lysis buffer,
sonicated, and centrifuged (10 min at 14 rpm at
4°C). Supernatants were collected and the pro-
tein contents were measured as above. Total
protein (300 g) was analyzed for each point
diluted 1:1.5 in block and sample buffer. Values
were calculated as picogram of BDNF per mil-
ligram of tissue protein and standardized to the
average of wt animals.
Western blot analysis. We analyzed the levels
of wt Htt by Western blot analysis using the
same monoclonal antibody against the wt Htt
fragment described above (Mab2166; Chemi-
con, Temecula, CA). Samples (n 3 per geno-
type and time point) were prepared and pro-
cessed by Western blot as described previously
(Dyer and McMurray, 2001). In brief, tissue
from the cerebral cortex or striatum was ho-
mogenate by sonication in 10l of radioimmu-
noprecipitation assay buffer (150 mM NaCl, 50
mM Tris-HCl, pH 8.0, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100, 0.1% SDS, 0.5%
sodium deoxycholate, 1 mM PMSF, 10 g/ml
Aprotinin, 1 g/ml Leupeptin) per milligram
of tissue. After homogenation, samples were
centrifuged twice at 12,000  g for 10 min.
Supernatant proteins (30 g) without head
denaturation were loaded in a 7.5% SDS-
PAGE and transferred to Immobilon-P
membranes (Millipore, Bedford, MA). Blots
were blocked in 3% nonfat dry milk in TBS-T
(150 mM NaCl, 20 mM Tris-HCl, pH 7.5,
0.05% Tween 20) and then incubated with
1:5000 of primary antibody in 0.5% nonfat
dry milk in TBS-T. After several washes in
TBS-T, blots were incubated with 1:1000 of
anti-mouse IgG HRP-conjugated (Promega)
and developed by ECL Western blotting anal-
ysis system (Bioscience Europe, Freiburg,
Germany). As loading controls, we reincu-
bated the membranes with a monoclonal anti-
-tubulin antibody (Sigma, St. Louis, MO).
Immunocytochemistry. To analyze the local-
ization of wt Htt, we performed immunocyto-
chemistry on M213 transfected with qp72. For
these experiments, expressing cells were not se-
lected by cell sorting to have a heterogenous
population in each well. In addition, we ana-
lyzed qp72 cells because their smaller and less
abundant aggregates allowed us to perform
more accurate localization at different levels of
aggregate formation. To detect wt Htt, we used
a monoclonal antibody against the Htt frag-
ment from aa 181– 810 (Mab2166; Chemicon).
This antibody only detects wt Htt because this
sequence is not included in the qp-mutant Htt
constructs used in the present study (Kazantsev
et al., 1999). Cells were fixed with 4% parafor-
maldehyde solution in PBS. After three washes,
cells were incubated with the primary antibody
(1:1000 in PBT buffer: PBS with 1% bovine se-
rum albumin and 0.3% Triton X-100) at 4°C
for 16 hr. The excess of antibody was washed out with PBS and thereafter
incubated with the secondary antibody (donkey anti-mouse-Texas Red
conjugated 1:300; Jackson Immuno Research, West Grove, PA), washed,
and mounted with Mowiol (Calbiochem, La Jolla, CA). Control avoiding
the primary antibody was performed and resulted in no signal. Photomi-
crographs were taken using a confocal microscope.
Histology. For neurotrophin in situ hybridization studies, mice were
killed by decapitation at 30 weeks of age, and brains were dissected out
Figure 2. Sequestering wt Htt downregulates BDNF. A, Within nontransfected neural stem cells derived from the striatum
(M213; d), wt Htt localizes in endocytic structures (open arrowheads). This localization is also detected in cells transfected with the
exon 1 of htt with 72 repeats (qp72) that do not present aggregates ( c) or that present small aggregates ( b). However, in cells that
express the qp72 construct and present large aggregates ( a), wt Htt is only detected into the aggregates (filled arrowheads). We
used the monoclonal antibody Mab2166 (Chemicon) to detect wt Htt (red; wt-Htt), whereas the mutant Htt was detected by the
endogenous EGFP of the fusion protein (green; m-Htt). B, No signal for wt Htt was detected in the aggregates (filled arrowheads)
in experiments avoiding the primary antibody. C, Western blot showing the levels of wt Htt in the cerebral cortex (Ctx) and in the
striatum (Str) from R6/1 animals at 20 weeks (lanes 1–3) or at 30 weeks (lanes 4 – 6) or from wild-type mice at 30 weeks (lanes
7–9). Note that there are no changes in the levels of wt Htt (Htt) in R6/1. The levels of-tubulin (Tub) are shown as a loading
control. D–F, The levels of BDNF in mutant htt mice do not modify the number or morphological aspects of the intranuclear
inclusions. Animals with mutant htt had intranuclear inclusions, which can be detected by mutant Htt or ubiquitin immunohisto-
chemistry. D, The same density of aggregates was detected in both immunostaining patterns per genotype. In addition, similar
results are shown in both R6/1 mice (bdnf/ httm) and bDM (bdnf/ httm), without significant differences between the two
groups. E, F, Double immunohistochemistry against NeuN (red) and ubiquitin (green) demonstrated the same intranuclear loca-
tion in both genotypes, containing mutant htt, with normal levels of BDNF (R6/1 mice; E) or with lower bdnf expression (bDM; F ).
Scale bars: A, 10m; B, 15m; (in E) E, F, 10m.
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and frozen in dry-ice cooled isopentane (n 4). Serial coronal cryostat
sections (14m) were processed for hybridization with radioactive ribo-
probes (Ibanez et al., 1992; Laurenzi et al., 1994; Lindefors et al., 1995) as
described previously (Canals et al., 2001). Antisense cRNA probe to de-
tect the transcripts of neurotrophins was prepared by in vitro transcrip-
tion using T3 or T7 RNA polymerase (Promega) and [ 33P]-UTP (Bio-
science Europe). For control experiments, sense cRNA probes were
obtained by in vitro transcription using the opposite RNA polymerase.
After deproteination and acetylation slices were incubated for 16 hr in a
humidified chamber at 53°C with 3 10 5 cpm of antisense probes in 150
l of hybridization mixture (50% formamide,
20 mM Tris-HCl, pH 7.6, 1 mM EDTA, pH 8.0,
0.3 M NaCl, 0.1 M dithiothreitol, 0.5 mg/ml
yeast tRNA, 0.1 mg/ml polyA RNA, 1 Den-
hardt’s solution, and 10% dextran sulfate). Af-
ter hybridization, slices were washed at high
stringency, dried, and exposed to Biomax MR
(Kodak, Rochester, NY) for 10 d.
Cresyl violet staining and immunohisto-
chemistry assays were performed on parafor-
maldehyde fixed material as described previ-
ously (Canals et al., 2001). Animals were
transcardially perfused with 4% paraformalde-
hyde solution in 0.1 M sodium phosphate, pH
7.2, at 15 d and 30 weeks of age. The brains were
postfixed for 2 hr in the same solution, cryo-
protected in incrementing 10 –30% sucrose/
PBS, and frozen in dry-ice cooled isopentane.
Serial horizontal cryostat sections (30m) sep-
arately (0.3 mm) were processed for cresyl vio-
let staining or immunohistochemistry.
Sections were processed as free-floating for
immunohistochemistry. To block endogenous
peroxidases, sections were incubated for 30
min with PBS containing 10% methanol and
3% H2O2. Sections were then washed three
times in PBS and blocked for 1 hr with 2–10%
normal serum in PBS. Tissue was then incu-
bated with the appropriated primary antibody
in PBS containing 2% normal goat serum for 16
hr at 4°C, except for DARPP-32, which was in-
cubated at room temperature. The following
antibodies were used: anti-neuronal-specific
nuclear protein (NeuN) 1:100 (Chemicon);
anti-DARPP-32, 1:10,000 (a generous gift from
Dr. H. C. Hemming, Rockefeller University,
New York, NY); anti-parvalbumin, 1:1250
(Sigma); anti-ubiquitin, 1:800 (Dako, High
Wycombe, UK), and anti-mutant Htt, 1:50
(EM48; Chemicon). Sections were washed
three times and incubated with a biotinylated
secondary antibody (1/220; Pierce, Rockford,
IL) for 1–2 hr at room temperature in the same
buffer as the primary antibody. The immuno-
histochemical reaction was developed using the
ABC kit (Pierce). No signal was detected in
controls avoiding the primary antibodies.
For double-labeling immunohistochemis-
try, slides were coincubated with the primary
antibodies anti-ubiquitin and anti-NeuN over-
night at 4°C. After three washes in PBS, the sec-
tions were coincubated with both secondary
antibodies (anti-rabbit FITC conjugated,
1:100, Vector Laboratories, Burlingame, CA;
and anti-mouse Texas Red conjugated, 1:200,
Jackson ImmunoResearch), washed, and mounted
with Mowiol (Calbiochem). Double-labeling
analysis was performed using a confocal
microscope.
For enkephalin and substance P analyses,
sections were processed by nonisotopic in situ hybridization as described
previously (Serrats et al., 2003). Frozen tissue sections were air dried,
fixed in 4% paraformaldehyde in PBS for 20 min at 4°C, washed once in
3 PBS and twice in 1 PBS for 5 min each, and incubated for 2 min at
21°C in a freshly prepared solution of predigested Pronase (Calbiochem)
at a final concentration of 24 U/ml in 50 mM Tris-HCl, pH 7.5, 5 mM
EDTA. Enzyme activity was stopped by immersion for 30 sec in 2 mg/ml
glycine in PBS. Tissues were finally rinsed in PBS and dehydrated
through a graded series of ethanol. Tissue sections were then covered
Figure 3. Lower BDNF levels cause earlier onset and more severe motor dysfunctions in mutant htt mice. A–C, bDM (bdnf/
httm) show more deficits on the rotarod than R6/1 mice (bdnf/ httm) tested at 16 rpm ( A), 24 rpm ( B), or 32 rpm ( C) ( p
0.001; F-Wald test).p 0.05 andp 0.005 compared with R6/1 mice (bdnf/ httm). bDM show earlier symptoms at all
revolutions assayed, and the onset of motor deficits (expressed as the first significant time point with respect to control animals;
A–C, arrowhead) showed advances from 6 – 8 weeks with respect to R6/1 mice (bdnf/ httm; A–C). D, In addition, bDM show
more severe symptoms. The total number of accumulated falls in the period examined is significantly different between mutant htt
mice with normal or low levels of BDNF. E, During early stages, the differences in the severity of motor deficits (measured as the
total number of falls up to the age of 16 weeks) between R6/1 mice and bDM are very large. D, E, ***p 0.001 compared with wt
mice (bdnf/ httwt);p 0.05 andp 0.005 compared with R6/1 mice (bdnf/ httm); ##p 0.005 and ###p 0.001
compared with bdnf heterozygous mice (bdnf/ httwt).
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with 100 l of hybridization buffer containing the probes, overlaid with
Nescofilm coverslips (Bando Chemical, Kobe, Japan), and incubated
overnight in humidified boxes at 42°C. Digoxigenin (DIG)-labeled
probes were diluted in hybridization solution: 50% formamide, 4 SSC
(1 SSC: 150 mM NaCl, 15 mM sodium citrate), 1Denhardt’s solution,
10% dextran sulfate, 1% Sarkosyl, 20 mM phosphate buffer, pH 7.0, 250
g/ml yeast tRNA and 500 g/ml salmon sperm DNA to a final concen-
tration of 1.5 nM. The oligodeoxyribonucleotide probes used were as
follows: the enkephalin probe was complementary to bases 513–542 of
the enkephalin sequence (GenBank accession number K02807) and was
synthesized on a 380 Applied Biosystem DNA synthesizer (Foster City
Biosystem, Foster City, CA), and the substance P probe was complemen-
tary to bases 223–270 from the preprotachykinin A sequence (GenBank
accession number M34183) and synthesized by Isogen Bioscience BV
(Maarssen, The Netherlands). They were 3-end labeled with terminal
deoxynucleotidyltransferase and DIG-11-dUTP (Roche, Mannheim,
Germany) as described previously (Schmitz et al., 1991). DIG-labeled
oligonucleotides were purified by ethanol precipitation and resuspended
in 200 l of TE (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, pH 8.0). After
hybridization, sections were washed four times (45 min each) in a buffer
containing 0.6 M NaCl and 10 mM Tris-HCl, pH 7.5, at 60°C.
Nonradioactive hybridization signal was developed as described pre-
viously (Landry et al., 2000). Briefly, after washing, the slides were im-
mersed for 30 min in a buffer containing 0.1 M Tris-HCl, pH 7.5, 1 M
NaCl, 2 mM MgCl2, and 0.5% bovine serum albumin and incubated
overnight at 4°C in the same solution with alkaline phosphate-
conjugated anti-digoxigenin-F(ab) fragments (1:5000; Roche). They
were then washed three times in the same buffer and twice in an alkaline
buffer (0.1 M Tris-HCl, pH 9.5, 0.1 M NaCl, and 5 mM MgCl2). Alkaline
phosphatase activity was developed by incubating the sections with 3.3
mg of nitroblue tetrazolium and 1.65 mg of bromochloroindolyl phos-
phate (Invitrogen) dissolved in 10 ml of alkaline buffer. The enzymatic
reaction was stopped by extensive rinsing in alkaline buffer with the
addition of 1 mM EDTA. The sections were then dehydrated and
air-dried.
Quantification of neurotrophin expression. The expression levels of
different neurotrophins [nerve growth factor (NGF), BDNF, NT-3,
and NT-4/5] were quantified on in situ hybridization films (n  4).
Consecutive sections (23–29 sections per animal) were scanned, and
mRNA levels were analyzed using the ImageJ program (National In-
stitute of Mental Health, Bethesda, MD). The intensity in a squared
area of 152.4 m 2 was quantified, and the background signal of the
same adjacent area outside of the brain was subtracted. Results were
expressed as the mean of several mice, and error bars represent the
SEM. Statistical analysis was performed using one-way ANOVA fol-
lowed by the LSD post hoc test.
Cell and inclusion counting. Brain, cortical, and striatal volumes were
measured by using Image tool program (The University of Texas Health
Center, San Antonio, TX) on a computer attached to an Olympus
(Ballerup, Denmark) microscope. Consecutive sections (14 –16 sections
per animal) were visualized, and the borders of the anatomical land-
marks were outlined. The volumes were calculated by multiplying the
sum of all sectional areas (square millimeters) by the distance between
successive sections (0.3 mm) as described previously (Canals et al., 2001).
All cell counts were performed blind with respect to genotype in 30-
week-old mice (n 4 –7 per each group and staining). Unbiased stereo-
logical counts of striatal cells were obtained from the entire neostriatum
using the computer-assisted stereology toolbox software (Olympus). The
dissector counting method was used to analyze coronal sections spaced
300 m apart. The counting frames were randomly sampled. We
counted the neuron-like cells in cresyl violet staining as the cells with a
large nonpyknotic nucleus with clear nucleoli. DARPP-32 neuron areas
were analyzed using the program AnalySIS Auto (Soft Imaging System,
Mu¨nster, Germany).
For intranuclear aggregate counting, three fields of 0.035 mm 2 were
analyzed in each section separated by 0.3 mm (n  4). The number of
inclusions was expressed in density. To obtain the number per cubic
millimeter, we divided the counts by the area corresponding to each field
examined and multiplied by the thickness of the section.
All results were expressed as the mean and the SEM of different mice.
Statistical analysis was performed using ANOVA followed by the LSD
post hoc test or a Student’s t test for independent samples.
Figure 4. BDNF levels control motor coordination in mutant htt mice. A–D, The decrease of
bdnf in mutant htt mice produces an uncoordinated walking footprint pattern. We analyzed the
following four parameters of footprints: A, the number of steps; B, the distance between two
consecutive steps; C, D, the distance between right and left frontbase and hindbase path, re-
spectively. bDM shows differences in the number and distance of steps (A, B) and in the front-
base width ( C). No differences were found in the hindbase pattern ( D). *p 0.05, **p
0.005, and ***p 0.001 compared with wt mice (bdnf/ httwt);p 0.05 andp
0.001 compared with R6/1 mice (bdnf/ httm); #p 0.05, ##p 0.005, and ###p 0.001
compared with bdnf heterozygous mice (bdnf/httwt). E, The levels of BDNF do not affect the
mouse’s ability to walk on a wire rod. Although we did not find statistical differences between
groups, animals with mutant htt and with normal or lower levels of BDNF had a higher tendency
to fall off the rod. The distance covered by the animals on the rod also shows the same effect,
with shorter runs in those animals expressing mutant htt.
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Results
The length and levels of CAG-repeat expression regulate
BDNF in vitro
Here, we examined whether the number of repeats and the levels
of mutant htt expression affect the production of BDNF (Fig.
1A,B). The levels of BDNF in supernatants of immortalized stri-
atal neurons transfected with constructs of exon 1 of mutant htt
containing 47 or 72 CAG repeats (qp47and qp72) were reduced
similarly (Fig. 1A) (qp47, 63.01 5.43%; qp72, 61.64 3.63% of
parental cells). However, supernatants from cells transfected with
exon 1 of the mutant htt with 103 repeats (qp103) was signifi-
cantly lower than qp47 and qp72 (Fig. 1A) (34.55  12.95% of
parental cells and 59.38  12.25% with respect to qp72). In ad-
dition, the amount of BDNF was inversely proportional to the
levels of expression of qp103 (Fig. 1B). In cells expressing low
qp103 levels, BDNF production was similar to that found in su-
pernatants from parental cells without significant differences.
These findings may help to explain the differences in BDNF levels
observed in distinct mouse models of HD. To evaluate the spec-
ificity of this effect, we also measured the levels of NT-3 in super-
natants from qp103 transfected cells, and we did not observe
modifications of this protein (104.52 18.9% of parental cells).
Generation of transgenic mutant htt mice with different
levels of BDNF
To analyze the role of BDNF in HD progression and to explore
whether the decrease of its expression is involved in the selective
vulnerability, we generated a bDM line by crossing R6/1 mice
(Mangiarini et al., 1996) with bdnf heterozygous mice (Ernfors et
al., 1994b) as described in Materials and Methods. We did not
detect any difference in life span between wt and bdnf/ mice.
However, R6/1 mice showed shorter survival as described by
Mangiarini et al. (1996). We examined the levels of BDNF,
mRNA, and protein in the cerebral cortex and striatum from
30-week-old mice (n 4 per genotype). We found that bdnf/
httm mice, the equivalent genotype to R6/1, have similar levels of
BDNF mRNA and protein to wt mice (Fig. 1C–G). In situ hybrid-
ization for bdnf showed that the expression of this neurotrophin
was only lower in bdnf heterozygous animals (bdnf/ httwt and
bdnf/ httm) (Fig. 1C–E). In addition, BDNF protein levels an-
alyzed by ELISA (Fig. 1F,G) showed the same levels in the cere-
bral cortex and in the striatum of the two genotypes with bdnf/
(in picogram per milligram of protein; striatum: wt, 46.81 5.97
and R6/1 genotype, 54.70  3.24; cerebral cortex: wt, 61.90 
5.52 and bdnf/ httm, 56.96 1.67). To rule out a genetic back-
ground effect, we also evaluated R6/1 mice. These mice showed
no changes in BDNF levels (data not shown). In addition, bDM
(bdnf/ httm; in picogram per milligram of protein; striatum:
30.96 1.41; cortex: 36.78 1.70) showed the same decrease in
BDNF levels as bdnf/ littermates with normal htt (bdnf/
httwt; in picogram per milligram of protein; striatum: 26.42 
Figure 5. Reduction of BDNF levels in mutant htt mice produces neuronal loss in the stria-
tum. A, Representative sections of DARPP-32 immunohistochemistry on wt mice (bdnf/
httwt), R6/1 mice (bdnf/ httm), bdnf heterozygous mice (bdnf/ httwt), and bDM
(bdnf/ httm). B, C, We used DARPP-32 immunostaining to measure the volume of the
cerebral cortex ( B) and the striatum ( C). B, The cerebral cortex shows the same atrophy in both
genotypes with mutant htt. C, In contrast, the striatal volume is significantly lower in bDM with
respect to R6/1 mice, indicating that the insufficient levels of this neurotrophin produce more
4
severe striatal degeneration. D, E, At 30 weeks, bDM have striatal neuronal loss, counted by
neuronal morphology in cresyl violet staining ( D) or by NeuN immunohistochemistry ( E). No
decrease in neurons was detected in other genotypes. F, G, In n3DM (nt-3/httm), the effects
observed result from the addition of striatal and cortical reduction observed in individual geno-
types, mutant htt and nt-3/. H, I, No differences in cell loss were observed between nt-3
heterozygous with or without mutant htt. Both genotypes (nt-3/ httwt and nt-3/ httm)
present a25% reduction. *p 0.05, **p 0.005, and ***p 0.001 compared with wt
mice (bdnf/ httwt or nt-3/ httwt); p  0.05 and p  0.001 compared with
bdnf/ httm or nt-3/ httm mice; #p 0.05, ##p 0.005, and ###p 0.001 compared
with bdnf or nt-3 heterozygous mice, respectively.
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2.98; cortex: 40.24  3.49) (Fig. 1F,G). We next analyzed
whether other neurotrophins compensate for the insufficient lev-
els of BDNF by modifying their levels of expression. In situ hy-
bridizations against NGF, NT-3, or NT-4/5 did not show changes
in the mRNA levels of these neurotrophins in any genotype stud-
ied (data not shown).
BDNF regulation is downstream of the aggregate formation
It has been proposed that this wt Htt-mediated BDNF regulation
can be associated to the sequestering of wt Htt into aggregates.
Our results showed that in nontransfected M213 cells, wt Htt is
localized in endocytic compartments, as described previously
(Kegel et al., 2000) (Fig. 2A). However, in M213 cells transfected
with mutant htt, wt Htt is also localized into aggregates, and in
cells with large aggregates, the endocytic wt Htt labeling disap-
peared (Fig. 2A). No signal was observed avoiding primary antibody
(Fig. 2B).
To test a correlation between the expression of BDNF and the
levels of wt Htt in vivo, we examined the levels of the endogenous
wt form in symptomatic R6/1 at 20 and 30 weeks in the cerebral
cortex and the striatum (n  3). Our results demonstrated that
the levels of the protein of wt Htt were not modified in the R6/1
compared with 30-week-old wt mice (Fig. 2C).
Our results also showed that modification of BDNF levels did
not alter the number and the localization of ubiquitinated aggre-
gates (Fig. 2D–F). We counted the density of aggregates contain-
ing mutant Htt by immunohistochemistry against mutant Htt or
ubiquitin in the striatum of both mutant htt genotypes, R6/1 mice
and bDM at 30 weeks of age (n 4). The number of aggregates
per cubic millimeter was not modified by decreased bdnf expres-
sion [mutant Htt-positive aggregates per cubic millimeter: R6/1
(bdnf/ httm), 126,100  6540; bDM (bdnf/ httm),
118,722 8169] (Fig. 2D). Similarly, the ubiquitination of these
aggregates showed no inter-group differences [ubiquitin-
positive aggregates per cubic millimeter: R6/1 (bdnf/ httm),
130,751  7416; bDM (bdnf/ httm), 127,695  7600] (Fig.
2D). We also performed double immunohistochemistry to locate
these inclusions. Aggregates in both genotypes had the same dis-
tribution pattern with a main intranuclear location (Fig. 2E,F).
Most striatal cells had at least one intranuclear aggregate (Fig.
2E,F). Similar results were observed in the cerebral cortex (data
not shown). Together, present findings suggest that BDNF regu-
lation is downstream of the aggregate formation.
The reduction of BDNF induces advanced and more severe
motor deficits in mutant htt mice
All animals that expressed mutant htt displayed a progressive
neurological phenotype. However, bDM showed more severe
symptoms. bDM had more tremors at rest and sudden move-
ments that resembled chorea (supplemental material, available at
www.jneurosci.org). The behavioral analyses of their motor abil-
ities on the rotarod apparatus showed that R6/1 mice began to
show significant differences from wt mice at 18 weeks at 24 and 32
rpm (Fig. 3B,C) and at 20 weeks of age at 16 rpm (Fig. 3A).
However, bDM showed significant motor alterations with re-
spect to wt or bdnf heterozygous mice from 10 weeks of age at 32
rpm (Fig. 3C) and 12 weeks at 16 and 24 rpm (Fig. 3A,B). There-
fore, the onset of motor disorders advanced between 6 and 8
weeks (at 24 rpm and 16 or 32 rpm, respectively) in animals with
a life span of 34 weeks (Mangiarini et al., 1996). The severity of
motor dysfunction was also affected in bDM. The progression of
movement deficits in bDM (bdnf/ httm) was more severe than
in R6/1 mice (bdnf/ httm; p  0.001; F-Wald test). Further-
more, the total number of falls during the entire period (30
weeks) was significantly higher in bDM (bdnf/ httm) than in
R6/1 mice (bdnf/ httm) (Fig. 3D). The impairment of rotarod
performance resulting from a decrease of BDNF in mutant htt
mice was 154%. This effect was especially drastic in the initial
period: up to 16 weeks of age, bDM showed 340% of rotarod test
impairment (Fig. 3E). The progression of motor dysfunction was
rapid in bDM, which were the only mice to reach the top number
of falls (Fig. 3A–C). Remarkably, bdnf heterozygous mice did not
show differences with respect to wt mice, indicating that the de-
crease of BDNF per se does not produce motor disturbances.
The instability of animals on the moving cylinder of the ro-
tarod may be attributable to the lack of motor coordination or
because of deficits in equilibrium, vision, or muscular strength.
Thus, we next measured walking coordination by quantitative
analysis of the footprint patterns (Fig. 4A–D). At 30 weeks of age,
R6/1 mice did not show alterations in the number of steps (Fig.
4A), stride length (Fig. 4B), frontbase width (Fig. 4C), or hind-
base width (Fig. 4D). However, bDM showed significant differ-
ences in all parameters studied except hindbase width (Fig. 4A–
D), suggesting that the lack of coordination contributes to
rotarod disturbance. We also analyzed other behavioral parame-
ters that might affect motor dysfunction. Equilibrium was as-
sessed for the four different genotypes (Fig. 4E). The groups did
not differ in their performance on a cylindrical wire rod, although
fall latency in mutant htt animals with normal or reduced BDNF
levels tended to go down (Fig. 4E). Similarly, no differences in the
visual cliff avoidance test or in muscular strength evaluated by the
wire hang test were observed between groups (data not shown).
We could not perform motor behavior analysis in n3DM be-
cause all nt-3 heterozygous mice were unable to perform the
tasks. Motor deficits in these mice have been described previously
(Ernfors et al., 1994b).
Neuronal cell loss in the striatum of bDM
Although all animals with mutant htt had less brain volume,
modification of bdnf alleles did not affect these changes (n 4 –7;
brain volume: bdnf/ httwt, 100 8.83%; bdnf/ httm, 81.75
6.80%; bdnf/httwt, 97.29  12.82%; bdnf/httm, 82.43 
13.81% with respect to wt). Similarly, the levels of bdnf expres-
sion did not affect the volume of the cortex, which was less in both
groups with mutant htt (Fig. 5A,B). In contrast, degeneration of
the striatum was observed in the bDM (Fig. 5A,C). These animals
showed a volume of 75.43  1.12% with respect to wt animals
(100 5.17%), which was significantly lower than the volume in
R6/1 striata (85.32  0.68% with respect to wt). In addition, a
decrease in BDNF levels caused neuronal loss in the striatum of
mutant htt transgenic mice. The estimated number of total neu-
rons counted by cresyl violet was down to 85.64 1.29% in bDM
with respect to wt mice (Fig. 5D). Similarly, the number of NeuN-
positive cells was 79.60 2.35% in bDM with respect to wt mice
(Fig. 5E). No differences were detected in the other genotypes,
either in cresyl violet or in NeuN-positive counts (cresyl violet:
bdnf/ httwt, 100  0.87%; bdnf/ httm, 96.93  3.72%;
bdnf/ httwt, 97.44 5.54% with respect to wt; NeuN-positive
cells: bdnf/ httwt, 100 7.04%; bdnf/ httm, 98.31 4.01%;
bdnf/ httwt, 95.80 8.90% with respect to wt).
To demonstrate the specific effect of BDNF, we generated a
n3DM line in which transgenic mice present different levels of
NT-3, another neurotrophin with protective effects on striatal
neurons (Perez-Navarro et al., 2000). The analyses of n3DM re-
vealed a decrease in the volume of both cortex and striatum (Fig.
5F,G) [cerebral cortex: nt-3/httm, 59.02 2.13% with respect
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to wt (nt-3/ httwt, 100 4.18%); stria-
tum: nt-3/ httm, 62.30  4.50% with
respect to wt (nt-3/ httwt, 100 
8.26%)]. However, this decrease in vol-
ume results from the addition of the inde-
pendent effects observed in R6/1 mice and
nt-3 heterozygous mice (Fig. 5F,G) [cere-
bral cortex: R6/1 mice (nt-3/ httm),
82.57  4.59%; nt-3/httwt, 68.90 
9.4% with respect to wt; striatum: R6/1
mice (nt-3/ httm), 78.52  1.84%; nt-
3/ httwt, 81.38 2.68% with respect to
wt]. Therefore, the effect of mutant htt is
similar in nt-3 heterozygous mice (nt-
3/ httm with respect to nt-3/ httwt:
cortex, 85.65  3.1%; striatum, 76.55 
5.5%) and in mice with normal NT-3 lev-
els (nt-3/ httm with respect to wt: cor-
tex, 82.57  4.59%; striatum, 78.52 
1.8%). The effect of this neurotrophin on
striatal neurons is similar in both NT-3
heterozygous genotypes in which the
number of neurons is reduced25% (Fig.
5H, I) (cresyl violet: nt-3/ httwt, 100 
4.98%; nt-3/ httm, 97.34  3.76%; nt-
3/ httwt, 75.59 6.79%; nt-3/ httm,
72.80 4.45% with respect to wt; NeuN-
positive cells: nt-3/ httwt, 100 4.69%;
nt-3/ httm, 96.68 3.46%; nt-3/ ht-
twt, 77.03 3.50%; nt-3/ httm, 77.76
2.70% with respect to wt).
We next analyzed whether neuronal
loss in the striatum is because of a deficit
during development or progressive de-
generation. bDM showed no neuronal al-
terations in the striatum at postnatal day
15 (n  4 – 6 per genotype). The striatal
volume of bDM was 104  4.18% with
respect to wt, and the number of NeuN-
positive neurons was 109.93  5.01% with
respect to wt. In addition, we analyzed the
striatal volume and neurons of animals that
had complete knock-out of the bdnf gene.
These animals showed a striatal volume of
98.87 3.53%, and the number of NeuN-
positive neurons was 105.49  6.06% with
respect to wt.
Specific degeneration of enkephalin
striatal subpopulation is controlled
by BDNF
One of the pathological characteristics of
HD is its specific pattern of degeneration.
Here, we show that the number of
medium-sized neurons immunostained
with DARPP-32 was reduced in R6/1 mice
(59  2% with respect to wt; 100  9%)
(Fig. 6A,B). However, DARPP-32-
positive neurons were fewer in bDM
(30 16% with respect to wt) (Fig. 6A,B).
We calculated the effect attributed to
lower BDNF levels in animals with mutant
htt by standardizing values for the R6/1
Figure 6. The striatal cells lost in bDM are enkephalin-positive neurons. A–C, At 30 weeks of age, bDM (bdnf/ httm) had great
atrophy of medium-sized striatal projection neurons, as demonstrated by DARPP-32 immunostaining. The number of DARPP-32-positive
neurons decreased in all mutant htt mice ( B). However, the lowest number of DARPP-32-positive neurons was detected in bDM. C, The
cross-sectional area of DARPP-32 neurons decreased in all animals that express mutant htt, although the area is significantly smaller in
bDM. D, E, The two neuronal subpopulations of medium-sized spiny neurons in the striatum were characterized by in situ hybridization. D,
The number of enkephalin-positive neurons (ENK) was dramatically less in bDM. The number of ENK-positive neurons was also less in R6/1
mice (bdnf/ httm) than in wt mice but only by a small amount. E, The differences between the two mutant htt groups are statistically
significant. In contrast, the decrease in substance P-positive neurons (SP) is similar in R6/1 mice (bdnf/ httm) and bDM (bdnf/
httm), without significant differences. F, We also analyzed the number of striatal interneurons by parvalbumin immunohistochemistry. No
differences were found between the four genotypes analyzed. *p 0.05, **p 0.005, and ***p 0.001 compared with wt mice
(bdnf/httwt);p0.05andp0.001comparedwithR6/1mice(bdnf/httm); #p0.05, ##p0.005,and ###p0.001
compared with bdnf heterozygous mice (bdnf/ httwt). Scale bar, 100m.
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mice, showing a reduction of 50 13% in bDM with respect to
R6/1 mice. No differences in the number of DARPP-32-positive
neurons were observed in bdnf heterozygous mice (87  14%
with respect to wt) (Fig. 6A,B).
The cross-sectional area of DARPP-32-positive neurons
showed a small reduction in R6/1 mice (bdnf/ httm, 85 3%
with respect to wt; 100  3%) (Fig. 6C). However, in bDM,
medium-sized cells were more atrophied with a significantly
lower soma area (72  1.9% with respect to wt) (Fig. 6C). In
contrast, we did not find loss of parvalbumin-positive inter-
neurons in any genotype analyzed (bdnf/ httwt, 100 3.2%;
bdnf/ httm, 95.6  9.2%; bdnf/httwt, 107.29  4.0%;
bdnf/httm, 102.6  7.9% with respect to wt) (Fig. 6 F).
We next characterized the subpopulations of striatal projec-
tion neurons by in situ hybridization (Fig. 6D,E). In bDM, the
number of enkephalin-positive neurons drastically fell to 47.20
0.99% with respect to wt (100  4.39%), whereas in R6/1, the
number of enkephalin-positive neurons decreased to only
84.32  2.10% with respect to wt (Fig. 6D). In contrast, the
number of substance P-positive neurons in the two genotypes
expressing mutant htt was not significantly different (bdnf/
httwt, 100 10.75%; bdnf/ httm, 77.10 7.02%; bdnf/httwt,
97.91 7.41%; bdnf/httm, 73.04 6.83% with respect to wt)
(Fig. 6E).
To further study the specific effect of BDNF on enkephalin-
ergic neurons, we administered 4.5 g of BDNF per day into the
striatum of 20-week-old R6/1 mice during 1 week (n 5) (Fig. 7).
This treatment enhanced the number of enkephalin-positive
neurons to 60.28 24.07% above the sham-R6/1 mice (Fig. 7A).
We also administered BDNF to 14-week-old bDM in which ex-
ogenous BDNF increased the number of enkephalinergic neu-
rons 127.09 31.42% above sham-bDM (Fig. 7A,B). However,
BDNF treatment did not alter the number of substance P-positive
neurons in R6/1 mice (12.86 15.25% above sham) or in bDM
(19.18 10.34% above sham) (Fig. 7C,D). In addition, prelimi-
nary behavioral analysis showed that bDM, which received uni-
lateral administration of BDNF, showed asymmetric rotations
induced by amphetamine (5 mg/kg). These mice showed 65.00
20.57 contralateral net rotations, whereas sham-bDM showed
40.00  23.18 ipsilateral net rotations ( p  0.0137). Thus,
present results suggest that BDNF restores some striatal functions
related to the increase in enkephalin expression.
Discussion
In the present study, we disrupted the expression of bdnf in an
HD mouse model by cross-mating bdnf / (Ernfors et al.,
1994b) and R6/1 mice (Mangiarini et al., 1996). The character-
ization of these mice demonstrates that endogenous BDNF reg-
ulates the onset and the severity of motor dysfunction. These
effects are caused by selective degeneration of enkephalin-
positive neurons in the striatum, which can be restored by ad-
ministration of exogenous BDNF.
It has been postulated that mutant Htt may act as a dominant-
negative over wt protein by capturing it into aggregates (Dyer and
McMurray, 2001). This effect could result in the loss of wt Htt
function in NRSF inhibition (Zuccato et al., 2003), causing
BDNF alterations. We observed that wt Htt colocalizes with mu-
tant Htt into the aggregates in cells that express mutant htt gene,
supporting the idea of a dominant-negative role for mutant Htt
in cell cultures. In addition, a decrease in mutant Htt-mediated
BDNF depends not only on the number of CAG repeats but also
on its levels of expression, because low amounts of mutant Htt
did not produce a decrease in BDNF levels. These data may ex-
Figure 7. Exogenous BDNF restores the enkephalin loss in mutant htt mice. A, B, Continuous
intrastriatal administration of BDNF (4.5g per day) during 1 week produces an increase in the
number of enkephalin-positive cells (ENK). This effect may be caused by the enhancement in the
enkephalin mRNA levels in both R6/1 mice (bdnf/ httm) and bDM (bdnf/ httm). C, D,
However, intrastriatal administration of BDNF in the same animals does not modify the levels of
substance P-positive neurons (SP). No differences were observed in PBS-infused animals
(sham) with respect to untreated animals, either in enkephalin- or in substance P-positive
neurons (data not shown). B, D, Representative photomicrographs of in situ hybridization for
enkephalin (ENK) and substance P (SP) in bDM injected with BDNF or PBS (Sham). Note that
after BDNF treatment, the enkephalin-positive neurons were detected around the injection site
but not in the injection core ( B).Ep 0.05 andEEp 0.005 compared with sham-operated
mice (Student’s t test). Scale bars: B, D, 100m.
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plain the differences observed in distinct mutant htt transgenic
mouse models. In fact, our findings showed that the transgenic
R6/1 mice, which express only one copy of the mutant 5-end of
the human htt gene carrying (CAG)115 (Mangiarini et al., 1996),
have normal levels of BDNF, which correlates with the normal
levels of wt Htt detected in these mice. However, R6/2 mice,
which express the transgene three times more than R6/1 and
carry 150 CAG repeats (Mangiarini et al., 1996), have decreased
levels of free wt Htt, which reduces BDNF concentrations (Zhang
et al., 2003). Within knock-in mouse lines, a dose-dependent
Htt-mediated BDNF decrease has also been established (Zuccato
et al., 2001). Our results also demonstrate that decreasing the
levels of BDNF in R6/1 mice does not alter the number or local-
ization of intranuclear aggregates in vivo. Similar results have
been described previously in cell culture (Saudou et al., 1998).
Together, all of these findings suggest that the number of CAG
repeats and its levels of expression modify the amount of wt Htt
available to retain the NRSF and consequently produce changes
in bdnf expression.
Besides this interaction between the expression of mutant htt
and BDNF, no evidence has correlated the decrease in BDNF with
the HD neuropathology. Our results show that the decrease in
BDNF levels produced more severe symptoms in an HD model.
bDM showed an early onset of motor dysfunction with signifi-
cant motor alterations 6 – 8 weeks before their littermates, R6/1
mice. In addition, the progression of movement deficits in bDM
was faster and more severe than in R6/1. We also found motor
disorders in the analysis of footprint patterns, which demon-
strated that only bDM have deficits in walking coordination.
Note that although bdnf knock-outs have alterations of sensory
neurons (Ernfors et al., 1994a; Jones et al., 1994), bdnf/ mice
with wt htt or mutant htt did not show deficits in the equilibrium,
visual test, or muscular strength. In addition, it has been shown
recently that the conditional BDNF-null mutant mice, which lack
this neurotrophin in the striatum, do not have motor alterations
(Baquet et al., 2004). These findings demonstrate that BDNF
affects brain nuclei that control motor coordination only in the
presence of mutant htt.
We next examined the neuronal populations that are affected
by BDNF in HD. The lower BDNF levels of bDM reduced striatal
volume without affecting the cerebral cortex. Similarly, neuronal
loss in the cerebral cortex has not been observed in transgenic
mutant htt mouse models (Mangiarini et al., 1996; Hodgson et al.,
1999; Shelbourne et al., 1999; Yamamoto et al., 2000; Slow et al.,
2003). These results indicate that downregulation of cortical bdnf
mRNA found in animal models and patients with HD (Zuccato et
al., 2001) primarily affects striatal neurons but not cortical struc-
tures. In fact, it has been described that BDNF protein only de-
creases in the striatum of HD patients and not in the cerebral
cortex (Ferrer et al., 2000). In support of this view, it has been
shown that cortical BDNF is transported anterogradely to the
striatum (Altar et al., 1997), and it can protect striatal neurons
from excitotoxicity (Martinez-Serrano and Bjorklund, 1996;
Perez-Navarro et al., 1999, 2000; Canals et al., 2001; Alberch et al.,
2002). Therefore, a decrease in the expression of cortical bdnf
participates in selective striatal damage.
HD advances to higher grades (1– 4) when specific striatal cell
death occurs (Vonsattel et al., 1985). We show that the specific
decrease of striatal volume in bDM is caused by a loss of striatal
neurons, which was only observed in our bDM model at 30
weeks. These findings are consistent with previous reports that
show that R6/1 (Mangiarini et al., 1996) and bdnf/mice (Jones
et al., 1994; Ivkovic et al., 1997) have the same number of striatal
neurons as wt mice. Thus, the lack of BDNF per se does not
induce degeneration of striatal neurons, but, together with the
presence of mutant htt, it produces striatal cell loss. This neuronal
loss is not attributable to a deficit during development, because
we did not observe alterations of the number of striatal neurons
in 15-d-old bDM. In addition, the effect of BDNF on striatal
neurons of HD mice is specific because no differences were de-
tected in nt-3 heterozygous mice with or without mutant htt. Our
results are in agreement with the decrease of BDNF, but not
NT-3, in the transgenic yeast artificial chromosome models
(Zuccato et al., 2001), which present loss of striatal neurons
(Hodgson et al., 1999). Similarly, reduced levels of BDNF are also
detected in R6/2 (Zhang et al., 2003), which show a rapid disease
progression and striatal degeneration (Menalled and Chesselet,
2002). It has been demonstrated that mutant htt causes context-
dependent neurodegeneration mediated by different N-terminal
Htt fragments in transgenic mice (Yu et al., 2003), similar to what
we observed for the regulation of BDNF expression.
Motor deficits in R6/1 animals are attributed to neuronal dys-
function of DARPP-32-positive neurons rather than to cell death,
because no loss of striatal neurons was observed in these mice.
DARPP-32 is downregulated in R6/1 mice, whereas calbindin
immunolabeling, another marker for medium-sized projection
neurons, is not modified (van Dellen et al., 2000). However, the
drastic decrease in DARPP-32-positive cells observed in bDM is
attributed to downregulation of the cellular marker and neuronal
death, because this population represents 95% of striatal neu-
rons. bDM showed a 50% reduction in DARPP-32-positive neu-
rons without any change in the number of parvalbumin-positive
interneurons. These striatal DARPP-32-positive neurons project
to the globus pallidus and substantia nigra via two separate sub-
populations, enkephalin- and substance P-positive neurons, re-
spectively, which have different sensitivity to mutant htt. The
analysis of each subpopulation demonstrated that the number of
enkephalin-positive neurons fell drastically in bDM. In contrast,
the levels of BDNF did not affect the number of substance
P-positive neurons. These results are coincident with previous
studies with R6/2 mice, which present a decrease of BDNF levels
(Zhang et al., 2003) and a 50% reduction of enkephalin mRNA
but not of the levels of substance P expression (Bibb et al., 2000).
In view of our results, which show that the deficit of endoge-
nous BDNF specifically regulates the levels of enkephalin in HD,
we next examined the effect of administration of this neurotro-
phin in mutant htt transgenic mice. The intrastriatal treatment
with BDNF produced a reversion of the loss of the enkephalin-
ergic phenotype in R6/1 and in bDM. This increase in the number
of enkephalinergic neurons is attributable to the recovery of
mRNA expression because only 20% of neurons are lost in bDM,
and no cell death is observed in R6/1 mice. These findings suggest
that atrophic or dysfunctional striatal neurons are recovered by
BDNF administration. Consistent with these results is the obser-
vation that 1 week administration of BDNF in vivo leads to overall
increased expression of enkephalin as well as an increase in the
number of striatal cells expressing enkephalin (Perez-Navarro et
al., 1999). In addition, our results from the circling behavior
induced by amphetamine administration suggest that increasing
enkephalin expression via BDNF administration may have func-
tional implication in HD mouse models. However, additional
experiments are required to improve the dose and the adminis-
tration strategies to perform long-term bilateral treatments.
In conclusion, our results demonstrate that BDNF plays a
pivotal role in the pathophysiology of HD. Although BDNF is not
an inductor of HD and the initial steps of this disorder may occur
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without BDNF alterations, we show that BDNF regulates the age
of onset and the severity of motor dysfunctions through the con-
trol of the survival of striatal enkephalinergic neurons. In addi-
tion, BDNF treatment restores the enkephalin levels in striatal
projection neurons, one of the most affected populations in HD.
Therefore, administration of BDNF or increasing endogenous
levels in HD patients may stop or delay illness progression.
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